Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation

Ann Intern Med. 1997 Apr 1;126(7):528-31. doi: 10.7326/0003-4819-126-7-199704010-00005.

Abstract

Background: Previous reports suggest that younger carriers of the factor V Leiden mutation are at greater risk for venous thromboembolism than are older carriers. However, available data on thromboembolic risk are limited.

Objective: To determine age-specific incidence rates of venous thromboembolism associated with the factor V Leiden mutation.

Design: Prospective cohort study.

Patients: 14,916 initially healthy men participating in the Physicians' Health Study who were followed from 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism.

Measurements: Polymerase chain reaction was used to determine factor V Leiden mutation status in 156 study participants who developed venous thromboembolism during follow-up and in 2406 study participants who remained free of vascular disease.

Results: Risks for venous thromboembolism in heterozygous carriers of factor V Leiden mutation increased with age at a rate significantly greater than that in noncarriers. Whereas incidence rates of venous thromboembolism were similar in men with and men without the factor V Leiden mutation who were younger than 50 years of age, incidence rate differences (per 1000 person-years of observation) between affected and unaffected men increased significantly from 1.23 (95% CI, -0.4 to 2.9) for those aged 50 to 59 years to 1.61 (CI, -0.5 to 3.7) for those aged 60 to 69 years of age to 5.97 (CI, 0.6 to 11.3) for those aged 70 years or older (P for trend = 0.008). For idiopathic venous thromboembolism, age-specific incidence rate differences between men with and without the factor V Leiden mutation increased significantly with age (P = 0.017). However, no significant relation was found for secondary events (P > 0.2).

Conclusions: The findings support the hypothesis that the pathogenesis of venous thromboembolism involves acquired as well as genetic risk factors and indicate that determination of factor V Leiden mutation status should not be limited to young patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Factor V / genetics*
  • Heterozygote*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Mutation*
  • Protein C / metabolism
  • Thrombophlebitis / epidemiology*
  • Thrombophlebitis / genetics*
  • United States / epidemiology

Substances

  • Protein C
  • Factor V